Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

C. Williams · SciRah

Researcher profile · Semantic Scholar

C. Williams

Share profile

C. Williams — researcher profile on SciRah

h-index: 25
Works: 94
Citations: 3,902

Most-cited papers

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.
W. Wierda, T. Kipps, J. Mayer, S. Stilgenbauer +16 more
2010Journal of Clinical Oncology610 citations Open access
Semantic Scholar
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.
P. Kottaridis, D. Milligan, R. Chopra, R. Chakraverty +17 more
2000Blood526 citations
Semantic Scholar
Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.
R. Chakraverty, K. Peggs, R. Chopra, D. Milligan +17 more
2002Blood361 citations
Semantic Scholar
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
G. Jackson, F. Davies, C. Pawlyn, D. Cairns +17 more
2019The Lancet Oncology314 citations Open access
Semantic Scholar
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.
M. Dimopoulos, D. Siegel, S. Lonial, J. Qi +15 more
2013The Lancet Oncology234 citations
Semantic Scholar
High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.
G. Cook, C. Williams, Julia M. Brown, D. Cairns +13 more
2014The Lancet Oncology142 citations Open access
Semantic Scholar
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
G. Cook, A. J. Ashcroft, D. Cairns, C. Williams +15 more
2016The Lancet Haematology136 citations Open access
Semantic Scholar
Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study
K. Jordan, I. Proskorovsky, P. Lewis, J. Ishak +6 more
2013Supportive Care in Cancer132 citations Open access
Semantic Scholar
A phase 2, randomized, double‐blind, placebo‐controlled study of siltuximab (anti‐IL‐6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma
R. Orlowski, L. Gercheva, C. Williams, Heather J. Sutherland +16 more
2015American journal of hematology/oncology124 citations Open access
Semantic Scholar
Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies.
K. Branson, R. Chopra, P. Kottaridis, G. McQuaker +11 more
2002Journal of Clinical Oncology119 citations
Semantic Scholar
Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)
C. Landgren, A. Chari, Y. Cohen, A. Spencer +17 more
2020Leukemia91 citations Open access
Semantic Scholar
Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.
K. Peggs, S. Mackinnon, C. Williams, S. D'Sa +8 more
2003Biology of Blood and Marrow Transplantation91 citations Open access
Semantic Scholar
Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial
JR Jones, D. Cairns, Wm Gregory, C. Collett +18 more
2016Blood Cancer Journal78 citations Open access
Semantic Scholar
Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma
I. Proskorovsky, P. Lewis, C. Williams, K. Jordan +3 more
2014Health and Quality of Life Outcomes77 citations Open access
Semantic Scholar
Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial
A. Österborg, T. Kipps, J. Mayer, S. Stilgenbauer +16 more
200850 citations
Semantic Scholar
Bortezomib, low‐dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma
R. Popat, H. Oakervee, C. Williams, M. Cook +9 more
2007British Journal of Haematology47 citations
Semantic Scholar
Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
G. Jackson, F. Davies, C. Pawlyn, D. Cairns +18 more
2019The Lancet Haematology45 citations Open access
Semantic Scholar
Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma.
G. Sidra, C. Williams, N. Russell, Sonya Zaman +2 more
2006Haematologica45 citations
Semantic Scholar
Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages; Results of the Phase III Myeloma XI Study
G. Jackson, F. Davies, C. Pawlyn, D. Cairns +17 more
201640 citations
Semantic Scholar
Lenalidomide Maintenance Significantly Improves Outcomes Compared to Observation Irrespective of Cytogenetic Risk: Results of the Myeloma XI Trial
G. Jackson, F. Davies, C. Pawlyn, D. Cairns +17 more
201733 citations
Semantic Scholar
Optimizing the management of patients with spinal myeloma disease
S. Molloy, M. Lai, G. Pratt, K. Ramasamy +23 more
2015British Journal of Haematology33 citations
Semantic Scholar
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial
G. Jackson, C. Pawlyn, D. Cairns, R. de Tute +19 more
2021PLoS Medicine32 citations Open access
Semantic Scholar
Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial
G. Jackson, F. Davies, C. Pawlyn, D. Cairns +19 more
2020Haematologica30 citations Open access
Semantic Scholar
A Phase I/II Study of Bortezomib and Low Dose Intravenous Melphalan (BM) for Relapsed Multiple Myeloma.
R. Popat, H. Oakervee, N. Foot, S. Agrawal +5 more
200527 citations
Semantic Scholar
Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia
W. Wierda, T. Kipps, J. Mayer, T. Robak +16 more
201025 citations
Semantic Scholar
Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma
S. Ahmedzai, J. Snowden, A. J. Ashcroft, D. Cairns +17 more
2019Journal of Clinical Oncology24 citations Open access
Semantic Scholar
Daratumumab Monotherapy for Patients with Intermediate or High-Risk Smoldering Multiple Myeloma (SMM): Centaurus, a Randomized, Open-Label, Multicenter Phase 2 Study
C. Hofmeister, A. Chari, Y. Cohen, A. Spencer +16 more
201724 citations
Semantic Scholar
Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study
A. Österborg, R. Jewell, Swami Padmanabhan-Iyer, T. Kipps +18 more
2015Haematologica23 citations Open access
Semantic Scholar
Phase II, randomized, double blind, placebo-controlled study comparing siltuximab plus bortezomib versus bortezomib alone in pts with relapsed/refractory multiple myeloma.
R. Orlowski, L. Gercheva, C. Williams, H. Sutherland +15 more
201221 citations
Semantic Scholar
Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial
S. Schey, Sarah R. Brown, Avie-Lee Tillotson, K. Yong +12 more
2015British Journal of Haematology19 citations
Semantic Scholar
Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four Trial.
Sarah R. Brown, C. Pawlyn, Avie-Lee Tillotson, Debbie Sherratt +7 more
2020Clinical Lymphoma, Myeloma & Leukemia18 citations
Semantic Scholar
Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open‐label, randomised, Phase III trial
G. Jackson, C. Pawlyn, D. Cairns, Alina Striha +19 more
2020British Journal of Haematology18 citations Open access
Semantic Scholar
The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long‐term follow‐up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open‐label, phase 3 trial
G. Cook, Kara-Louise Royle, S. O'Connor, D. Cairns +18 more
2019British Journal of Haematology18 citations Open access
Semantic Scholar
Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive)
K. Yong, S. Hinsley, H. Auner, C. Bygrave +15 more
2021Haematologica16 citations Open access
Semantic Scholar
Etoposide, methylprednisolone, cytarabine and cisplatin successfully cytoreduces resistant myeloma patients and mobilizes them for transplant without adverse effects
S. D'Sa, K. Yong, C. Kyriakou, S. Bhattacharya +7 more
2004British Journal of Haematology16 citations
Semantic Scholar
Response Adapted Induction Treatment Improves Outcomes for Myeloma Patients; Results of the Phase III Myeloma XI Study
G. Jackson, F. Davies, C. Pawlyn, D. Cairns +17 more
201615 citations
Semantic Scholar
Cytomegalovirus infection and disease after autologous CD34-selected peripheral blood stem cell transplantation for multiple myeloma: no evidence of increased incidence based on polymerase-chain-reaction monitoring.
K. Peggs, S. Ings, P. Kottaridis, K. Yong +3 more
2000Blood15 citations
Semantic Scholar
Lenalidomide induction and maintenance therapy for transplant eligible myeloma patients: Results of the Myeloma XI study.
G. Jackson, F. Davies, C. Pawlyn, D. Cairns +16 more
201714 citations
Semantic Scholar
The Safety, Pharmacokinetics and Pharmacodynamics of KW-2478, a Novel Hsp90 Antagonist, in Patients with B-Cell Malignancies: A First-in-Man, Phase I, Multicentre, Open-Label, Dose Escalation Study
J. Cavenagh, K. Yong, J. Byrne, J. Cavet +6 more
200813 citations
Semantic Scholar
Expert radiological review of skeletal surveys identifies additional abnormalities in 23% of cases: further evidence for the value of myeloma multi‐disciplinary teams in the accurate staging and treatment of myeloma patients
Jas Singh, K. Fairbairn, C. Williams, E. Dasgupta +2 more
2007British Journal of Haematology13 citations Open access
Semantic Scholar
Correlation Between Serum Ofatumumab Concentrations, Baseline Patient Characteristics and Clinical Outcomes in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ofatumumab.
A. Österborg, B. Rønn, R. Jewell, T. Kipps +19 more
200911 citations
Semantic Scholar
Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial.
C. Parrish, C. Morris, C. Williams, D. Cairns +12 more
2016Biology of Blood and Marrow Transplantation10 citations Open access
Semantic Scholar
A non myeloablative regimen for allografting high-risk patients: Low toxicity, stable engraftment without GVHD, disease control and potential for GVL with adoptive immunotherapy.
P. Kottaridis, R. Chakraverty, D. Milligan, S. Chakrabarti +14 more
199910 citations
Semantic Scholar
Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM)
O. Landgren, M. Cavo, A. Chari, Y. Cohen +18 more
2018Blood9 citations Open access
Semantic Scholar
Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): First Final Analysis of the Phase 2 Muk Five Study
K. Yong, Samantha Hinsley, H. Auner, Debbie Sherratt +14 more
20179 citations
Semantic Scholar
The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma
Sarah R. Brown, S. Hinsley, M. Ballesteros, Sue Bourne +10 more
2016BMC Hematology9 citations Open access
Semantic Scholar
An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR‐MM)
X. Leleu, E. Terpos, R. G. Sanz, J. Cooney +6 more
2016American journal of hematology/oncology9 citations Open access
Semantic Scholar
A Phase I/II Trial of Bortezomib, Low Dose Intravenous Melphalan and Dexamethasone for Patients with Relapsed Multiple Myeloma.
R. Popat, C. Williams, M. Cook, C. Craddock +6 more
20069 citations
Semantic Scholar
A Quadruplet Regimen Comprising Carfilzomib, Cyclophosphamide, Lenalidomide, Dexamethasone (KCRD) Vs an Immunomodulatory Agent Containing Triplet (CTD/CRD) Induction Therapy Prior to Autologous Stem Cell Transplant: Results of the Myeloma XI Study
G. Jackson, F. Davies, C. Pawlyn, D. Cairns +17 more
2018Blood8 citations
Semantic Scholar
Mineral status in canine medial coronoid process disease: a cohort study using analysis of hair by mass spectrometry
Mike Davies, J. West, C. Williams, David S. Gardner
2017The Veterinary Record8 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Jenner×17
Invite
M. Jenner — researcher profile on SciRah
G. Cook×17
Invite
G. Cook — researcher profile on SciRah
D. Cairns×16
Invite
D. Cairns — researcher profile on SciRah
G. Morgan×15
Invite
G. Morgan — researcher profile on SciRah

×15

Invite

F. Davies — researcher profile on SciRah

Invite

K. Yong — researcher profile on SciRah

Invite

M. Kaiser — researcher profile on SciRah

Invite

R. Owen — researcher profile on SciRah

Invite

C. Pawlyn — researcher profile on SciRah

Invite

M. Garg — researcher profile on SciRah

Invite

N. Russell — researcher profile on SciRah

Invite

W. Gregory — researcher profile on SciRah